News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,485 Results
Type
Article (14906)
Company Profile (299)
Press Release (266274)
Multimedia
Podcasts (77)
Webinars (11)
Section
Business (79853)
Career Advice (161)
Deals (13343)
Drug Delivery (39)
Drug Development (50706)
Employer Resources (31)
FDA (5837)
Job Trends (5168)
News (145118)
Policy (10079)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (922)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21770)
ALS (124)
Alzheimer's disease (1028)
Antibody-drug conjugate (ADC) (239)
Approvals (6029)
Artificial intelligence (257)
Autoimmune disease (109)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (342)
Cancer (3102)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (216)
CDC (5)
Cell therapy (558)
Cervical cancer (14)
Clinical research (43643)
Collaboration (1141)
Company closure (2)
Compensation (584)
Complete response letters (39)
COVID-19 (1101)
CRISPR (86)
C-suite (540)
Cystic fibrosis (111)
Data (4287)
Denatured (14)
Depression (91)
Diabetes (253)
Diagnostics (1377)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (211)
Earnings (31628)
Editorial (24)
Employer branding (4)
Employer resources (29)
Events (51614)
Executive appointments (620)
FDA (7573)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (974)
Gene editing (180)
Generative AI (21)
Gene therapy (483)
GLP-1 (502)
Government (1146)
Grass and pollen (3)
Guidances (166)
Healthcare (6613)
HIV (18)
Huntington's disease (42)
IgA nephropathy (74)
Immunology and inflammation (185)
Immuno-oncology (38)
Indications (64)
Infectious disease (1205)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (164)
Interviews (18)
IPO (7342)
IRA (12)
Job creations (869)
Job search strategy (129)
JPM (39)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1403)
Liver cancer (41)
Longevity (11)
Lung cancer (418)
Lymphoma (245)
Machine learning (24)
Management (7)
Manufacturing (374)
MASH (130)
Medical device (2661)
Medtech (2669)
Mergers & acquisitions (6615)
Metabolic disorders (720)
Multiple sclerosis (100)
NASH (13)
Neurodegenerative disease (227)
Neuropsychiatric disorders (69)
Neuroscience (1938)
Neurotech (1)
NextGen: Class of 2026 (2033)
Non-profit (865)
Now hiring (29)
Obesity (326)
Opinion (125)
Ovarian cancer (129)
Pain (101)
Pancreatic cancer (158)
Parkinson's disease (231)
Partnered (12)
Patents (300)
Patient recruitment (321)
Peanut (43)
People (26637)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15460)
Phase 2 (20271)
Phase 3 (12819)
Pipeline (3185)
Policy (89)
Postmarket research (854)
Preclinical (6535)
Press Release (30)
Prostate cancer (143)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (637)
Real estate (1448)
Recruiting (12)
Regulatory (9879)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (20)
RSV (16)
Schizophrenia (121)
Series A (180)
Series B (135)
Service/supplier (1)
Sickle cell disease (76)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2004)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (334)
Venture capital (67)
Weight loss (171)
Women's health (25)
Worklife (2)
Date
Today (64)
Last 7 days (305)
Last 30 days (1429)
Last 365 days (17871)
2026 (1446)
2025 (18099)
2024 (20555)
2023 (22416)
2022 (26825)
2021 (27818)
2020 (23368)
2019 (16235)
2018 (11746)
2017 (13755)
2016 (11854)
2015 (14353)
2014 (10396)
2013 (7490)
2012 (7550)
2011 (7616)
2010 (7430)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (70)
Arkansas (5)
Asia (18238)
Australia (3108)
California (7029)
Canada (1826)
China (766)
Colorado (243)
Connecticut (248)
Delaware (234)
Europe (39149)
Florida (893)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (394)
India (35)
Indiana (159)
Iowa (8)
Japan (218)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (734)
Massachusetts (5541)
Michigan (108)
Minnesota (246)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1636)
New Mexico (13)
New York (1746)
North Carolina (819)
North Dakota (6)
Northern California (3448)
Ohio (177)
Oklahoma (11)
Oregon (24)
Pennsylvania (1268)
Puerto Rico (9)
Rhode Island (25)
South America (214)
South Carolina (9)
Southern California (2785)
Tennessee (40)
Texas (900)
United States (23169)
Utah (96)
Virginia (135)
Washington D.C. (37)
Washington State (587)
West Virginia (1)
Wisconsin (43)
281,485 Results for "kyn therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cognision Announces Partnership with Kynexis to Utilize its COGNISION® System in a Phase 2 Trial of KYN-5356 in Subjects with Schizophrenia
November 17, 2025
·
3 min read
Press Releases
Kynexis Announces First Patient Dosed in Phase 2 Clinical Trial of KYN-5356 for Cognitive Impairment Associated With Schizophrenia
October 1, 2025
·
3 min read
Drug Development
Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
Kynexis announced today that the first healthy volunteers have been dosed in its first-in-human phase 1 study of KYN-5356. KYN-5356, a clinical-stage small molecule targeting a key enzyme in the kynurenine pathway known as KAT-II, is being developed for cognitive impairment associated with schizophrenia (CIAS).
January 4, 2024
·
1 min read
Press Releases
Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia
December 18, 2024
·
3 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Press Releases
Altamira Therapeutics to Present at mRNA-Based Therapeutics Summit
January 26, 2026
·
4 min read
Press Releases
Lexeo Therapeutics Announces Key Leadership Appointments Strengthening Cardiovascular Expertise Alongside Updates to Strategic Partnership for Novel Cardiac RNA Therapeutics
January 28, 2026
·
7 min read
Press Releases
Silexion Therapeutics to Attend 7th Annual RNAi-Based Therapeutics Summit
January 22, 2026
·
1 min read
Press Releases
Swiss Rockets Group and Alloy Therapeutics Partner to Advance Radioligand Therapeutics in Oncology
January 12, 2026
·
3 min read
Press Releases
Force Therapeutics Celebrates 2025 Research Impact
January 9, 2026
·
2 min read
1 of 28,149
Next
